T2 Biosystems Announces Conversion of Approximately Twenty Percent of CRG Term Loan into Equity
LEXINGTON, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens...
Diagnostics
Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets
SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic...
Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities
PRESS RELEASE - REGULATED INFORMATION 30 June 2023, 7:00 CEST Disclosure of Outstanding Voting Securities Mechelen, Belgium, 30 June 2023...
Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT™ Clinical Trials at SNMMI Annual Meeting
ReSPECT-GBM Phase 1 recurrent glioblastoma trial demonstrates safety and overall survival correlation with absorbed radiation dose ReSPECT-LM Phase 1/Part A...
BioPorto Announces Submission of Response to FDA Additional Information Letter
June 29, 2023News release BioPorto Announces Submission of Response to FDA Additional Information Letter COPENHAGEN, DENMARK and BOSTON, MA, June...
Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing at the ICGEB
VANCOUVER, British Columbia, June 28, 2023 (GLOBE NEWSWIRE) -- June 28, 2023 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB)...
LifeArc strengthens Board of Trustees with new appointments
LifeArc strengthens Board of Trustees with new appointments 27 June 2023: LifeArc, the self-funded medical research organisation, announces today that...
Oncocyte Begins Manufacturing Transplant Blood Test
Over 1 million annual testing opportunities in US Q4 targeted for early access launch IRVINE, Calif., June 27, 2023 (GLOBE...
Assure Holdings Expands Service Offerings to Address the High Growth EEG Services Market
Signs Diagnostics Services Agreement with Neurovative DiagnosticsDENVER, June 27, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”)...
CENTOGENE and Lifera, a Biopharma Company Owned by the PIF, Enter Strategic Collaboration – Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing and Securing CENTOGENE $30 Million Investment
Joint Venture (JV) combines CENTOGENE's global leadership in multiomics with local insight of Lifera, a biopharmaceutical company wholly-owned by the...
OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe
Patent EP 3 332 028 B1 granted by the European Patent Office covers the identification and use of genomic variants...
OpGen’s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments
Following final assembly and successful testing, a batch of ten Unyvero A30 instrument systems has been receivedLatest C-Series Unyvero A30...
Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board
HEIDELBERG, Germany, June 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company...
HMNC Brain Health to Participate in the Psychedelic Science Conference 2023 and the H.C. Wainwright & Co. 4th Annual Neuropsychiatry Conference
MUNICH, Germany, June 21, 2023 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “company”), a global clinical-stage biopharmaceutical company,...
BioPorto A/S announces results of rights issue
June 21, 2023Announcement no. 11 BioPorto A/S announces results of rights issue COPENHAGEN, Denmark and BOSTON, MA, USA, June 21,...
Emergex and Brazil’s IBMP Announce Clinical Development Collaboration for T Cell-Priming Immune Set-Point Candidates
Emergex and Brazil’s IBMP to co-fund Phase II and Phase III studies of Emergex’s Dengue Fever and Betacoronavirus T cell-priming...
HMNC Brain Health Begins Phase 2 Study for Personalized Treatment of Stress-Axis Related Major Depressive Disorder (MDD)
The Company’s Nelivabon Program Pairs Novel Compound with Companion Diagnostics to Treat MDD patientsMUNICH, Germany, June 20, 2023 (GLOBE NEWSWIRE)...
Bone Health Technologies to Present Clinical Data from Pivotal Trial of Wearable Treatment for Osteopenia in Post-Menopausal Women at Endo 2023
Per Protocol Participants saw an 85% Reduction in the Loss of Vertebral Bone Density in One YearCHICAGO, June 16, 2023...
QIAGEN provides reminder on settlement mechanics of 2023 and 2024 convertible notes
Venlo, the Netherlands, June 16, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today a...
Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
AUSTIN, Texas, June 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted...